Description

The Urine CrossLaps ^® EIA is an enzyme immunosorbent assay for quantitative determination of degradation products of C-terminal telopeptides of Type-I collagen in human urine.

Features

·         Prediction of long-term skeletal response to anti-resorptive therapies

·         Patient motivation and compliance

·         Assessment of bone resorption in patients

Physiology

·         Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primarily in bone¹. During renewal of the skeleton, type I collagen is degraded, and small peptide fragments are excreted into the urine. These fragments can be measured by the Urine CrossLaps ^® EIA and has been reported as a useful tool for follow up of anti-resorptive treatment of patients with metabolic bone diseases.

AssayDetails

References

1.     1. Bjarnason et al., Bone 26, 561-569 (2000)